{"entity":{"id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","aka":[],"tldr":"A phase 3 trial of Neladalkib, Alectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvalent Inc., now recruiting.","summary":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC is a phase 3 interventional study registered as NCT06765109 by Nuvalent Inc., with 450 participants planned, started 2025-07-17 and due to reach its primary completion in 2029-12. Interventions recorded: Neladalkib (NVL-655), Alectinib. Conditions listed: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06765109","url":"https://clinicaltrials.gov/study/NCT06765109"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["neladalkib","alectinib"],"companies":["nuvalent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06765109","phase":"3","setting":"A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)","sponsor":"Nuvalent Inc.","enrolled":450,"outcomes":[]},"route":"/trials/nct06765109/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/"},{"id":"neladalkib","kind":"drug","name":"Neladalkib","route":"/drugs/neladalkib/"}],"company":[{"id":"nuvalent","kind":"company","name":"Nuvalent","route":"/companies/nuvalent/"}]}}